A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Twenty-five percent inhaled nitrous oxide improves symptoms of treatment-resistant major depression with fewer adverse effects than the 50% concentration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a Phase 2 trial of 25 and 50% inhaled nitrous oxide for TRD (n = 24) found significant improvement in depressive symptoms in both nitrous oxide groups”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [180]
In the citing paper
“with a significantly lower rate of adverse events in the 25% nitrous oxide group [180]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [180]
In the citing paper
“The antidepressant effects of N2O are mediated through antagonism of the metabotropic glutamatergic NMDA receptors (121).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [121]
In the citing paper
“Nagele and colleagues found that inhaled N2O at a concentration of either 25% or 50% significantly reduced scores on the Hamilton Depression Rating Scale (HDRS) at week 2 in patients with treatment resistant depression.”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [121]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
(2018) · The SAGE Encyclopedia of Educational Research, Measurement, and Evaluation · doi:10.4135/9781506326139.n404 · Cited by 1,528
Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin
Jevtović-Todorović, V., Todorovć, S. M., Mennerick, S., Powell, S., Dikranian, K., Benshoff, N., Zorumski, C. F., & Olney, J. W. (1998) · Nature Medicine · doi:10.1038/nm0498-460 · Cited by 676
Self-citationA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482 · cited 1×
“INTRODUCTION Treatment-resistant major depression (TRMD) is a severe form of major depressive disorder (MDD) in which patients fail to respond to multiple standard antidepressant treatments (1, 2).”
BackgroundAbdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Gibbons, R. D., Brown, C. H., Hur, K., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2048 · Cited by 291 · cited 2×
“We note, however, that for the entire 3-month treatment regimen, which involved two treatments with nitrous oxide, a median reduction of 11 HDRS-21 points was observed, which is much larger than that typically seen for traditional antidepressant trials (15, 16).”
BackgroundMethodSelf-citation
Cited by
Items 101–133 of 133
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0007
(2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.002.0003
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0004
What Is Psychedelic Experience?
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0002
(2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.002.0005
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0003
Spitzer, M. (2023) · Nervenheilkunde · doi:10.1055/a-2136-5473
Janski, A. M., Hristidis, V. C., Zorumski, C. F., & Conway, C. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00064-6
Self-citationThe Role of Rapid-Acting Antidepressants in Suicidal Crisis Management
Lengvenytė, A., Sarchiapone, M., Iosue, M., & Courtet, P. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.016
The use of inhaled gases in psychiatry
Hristidis, V. C., Nägele, P., Palanca, B. J. A., Tadler, S. C., Mickey, B. J., Gott, B. M., & Conway, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00016-1
Self-citationCichon, J., Joseph, T. T., Lu, X., Wasilczuk, A. Z., Kelz, M. B., Mennerick, S. J., Zorumski, C. F., & Nägele, P. (2024) · Research Square · doi:10.21203/rs.3.rs-5141491/v1
Self-citationSviridova, I. K., Гольдберг, М. А., Кирсанова, В. А., Akhmedova, S. A., Krokhicheva, P. A., R., K., Ns, S., & Komlev, V. S. (2024) · Cardiometry · doi:10.18137/cardiometry.2024.33.conf.9
Zhukova, G. V., Frantsiyants, E. M., Kharagezov, D. A., Shikhlyarova, A. I., Kaplieva, I. V., Mirzoyan, E. A., Milakin, A. G., & S., Z. (2024) · Cardiometry · doi:10.18137/cardiometry.2024.33.conf.14
Tumor treating field (TTF) therapy
Inui, T. (2024) · Cardiometry · doi:10.18137/cardiometry.2024.33.conf.1
Protective effect by melatonin in an experiment with transplantable melanoma B16
Kondashevskaya, M. V., Kozlova, M. A., Anurkina, A. I., Kasabov, K. A., & Areshidze, D. A. (2024) · Cardiometry · doi:10.18137/cardiometry.2024.33.conf.7
Li, N., Wang, Z., Huang, J., Sun, S., Zhu, J., Li, X., & Hu, B. (2024) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm62325.2024.10822512
“Major depressive disorder (MDD) is a severe psychiatric disorder causing high rates of disability and suicide [1], with a lifetime prevalence of 10%-20% [2].”
Provaznikova, B., Olbrich, S., Seifritz, E., Haas, M., & Kronenberg, G. (2025) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2025.100261
No Laughing Matter: Nitrous Oxide and Depression
Williams, E., & Cowen, P. J. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100551
“Subsequently they found equivalent antidepressant effects with better-tolerated 25% nitrous oxide (4).”
Kronenberg, G., Bankwitz, A., Provaznikova, B., Müller, M., Quednow, B. B., Seifritz, E., & Olbrich, S. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-096825
“30 So far, the limited literature on N 2 O mainly focused on depression (eg, adjunctive N 2 O therapy in major depression 31 ; so-called treatment-resistant depression 32–34 and bipolar depression).”
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Ketamine for neuropathic pain: Animal and human studies
Dahan, A., Niesters, M., Sarton, E. Y., & van Velzen, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00016-3
Zhao, T., Guo, X., Shi, Z., Xu, H., Deng, S., Tang, H., Cai, H., & Song, X. (2025) · Current Neuropharmacology · doi:10.2174/011570159x388095251029043707 · Cited by 1
Salamé, A., Bulteau, S., Robert, G. H., Vandevelde, A., Gissot, V., Agier, M., Gallet, Q., Nkodo, J., Leroy, V., Brunault, P., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103860
“32 A major challenge to blinding in psychedelic studies, including those involving (es)ketamine, is the presence of acute dissociative effects, which account for a substantial proportion of blinding failures.”
Wei, X., Xu, S., & Zhu, Z. (2026) · Current Neuropharmacology · doi:10.2174/011570159x458197260226055817
“Notably, N 2 O has also demonstrated rapid and sustained efficacy in treating patients with depression [67-69].”
Emerging Therapeutic Interventions for Treatment‑Resistant Depression
Tamez, M. C. C., Scaini, G., & Quevedo, J. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_26
Psychedelics: Future Therapeutics in Major Depression?
Olivier, B., & Olivier, J. D. A. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_25
Valtonen, P., Järventausta, K., Huhtala, H., Rantamäki, T., Uotila, J., Laivuori, H. M., & Kalliomäki, M. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.03.075
Kong, W., Sun, Z., Zhang, W., Li, X., Zhu, J., & Hu, B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111791
Annequin, D. (2025) · Dunod eBooks · doi:10.3917/dunod.poisb.2025.01.1405
Propofol for depression: mechanisms and therapeutic potential
Yu, D., Liao, Y., Li, J., Zheng, A., Meng, X., Gong, S., Li, C., & Kunwei, W. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1876988
“A subsequent phase 2 trial further established the ef fi cacy and safety of nitrous oxide for treatment-resistant major depression (Nagele et al., 2021).”
The Evolving Therapeutic Role of Nitrous Oxide
Wentling, J. G., Witt, A. J. D., Howard, J. T., Shekoohi, S., & Kaye, A. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_6
History of Anesthesia Therapeutics
Liu, H., & Kaye, A. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_1
Metadata
- Authors
- Nagele, P., Palanca, B. J., Gott, B., Brown, F., Barnes, L., Nguyen, T., Xiong, W., Salloum, N. C., Espejo, G. D., Lessov-Schlaggar, C. N., Jain, N., Cheng, W. W. L., Komen, H., Yee, B., Bolzenius, J. D., Janski, A., Gibbons, R., Zorumski, C. F., & Conway, C. R.
- Affiliations
- Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL 60637, USA.
- Washington University in St. Louis (US)
- University of Chicago (US)
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2021-06-09
- Volume
- 13
- Issue
- 597
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3170628472
- Cited by
- 133
- References
- 29
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 26 · 2023: 52 · 2022: 15 · 2021: 5
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Brain and Behavior Research Foundation (24593)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- major depressive disorder, treatment-resistant depression, adverse effects, depression treatment
- MeSH terms
- Antidepressive Agents, Depression, Major Depressive Disorder, Double-Blind Method, Humans, Nitrous Oxide, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.